Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
VeracyteVCYT | Open-market sale10b5-1 plan | 06/18 | 06/22 | 3,729 sh2 trades | $52.89avg. | $197,223.95 | −19.8% | |
Marc StapleyCEO | VeracyteVCYT | Open-market sale10b5-1 plan | 06/04 | 06/04 | 138,051 sh | $50.12 | $6,919,116.12 | −23.9% |
VeracyteVCYT | Open-market sale10b5-1 plan | 06/04 | 06/04 | 3,561 sh2 trades | $49.73avg. | $177,074.49 | −2.0% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 06/04 | 06/04 | 3,176 sh2 trades | $49.76avg. | $158,047.12 | −2.3% | |
John LeiteGlobal Chief Commercial Off | VeracyteVCYT | Open-market sale10b5-1 plan | 06/04 | 06/04 | 13,975 sh | $50.07 | $699,728.25 | −9.6% |
Jonathan WygantVP, Chief Accounting Officer | VeracyteVCYT | Open-market sale | 05/22 | 05/27 | 24,000 sh | $45.40 | $1,089,600 | −34.6% |
Robert S. EpsteinDirector | VeracyteVCYT | Open-market sale10b5-1 plan | 05/20 | 05/22 | 10,000 sh | $44.01 | $440,100 | −16.0% |
VeracyteVCYT | Open-market sale10b5-1 plan | 05/06 | 05/08 | 10,204 sh2 trades | $39.03avg. | $398,211.1 | −6.6% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 03/04 | 03/06 | 45,523 sh2 trades | $35.98avg. | $1,637,718.76 | −11.3% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 03/04 | 03/06 | 18,341 sh2 trades | $36.14avg. | $662,896.53 | −12.3% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 03/04 | 03/06 | 6,658 sh2 trades | $35.55avg. | $236,708.02 | −6.6% | |
John LeiteChief Commercial Officer-CLIA | VeracyteVCYT | Open-market sale10b5-1 plan | 03/04 | 03/06 | 5,260 sh | $35.19 | $185,099.4 | −4.7% |
Phillip G. FebboChief Scientific & Med Officer | VeracyteVCYT | Open-market sale10b5-1 plan | 03/02 | 03/04 | 13,425 sh | $36.16 | $485,448 | −10.3% |
VeracyteVCYT | Open-market sale10b5-1 plan | 25/12/16 | 25/12/17 | 10,739 sh2 trades | $43.14avg. | $463,228.07 | −13.7% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 25/12/05 | 25/12/08 | 20,000 sh3 trades | $45.45avg. | $908,962.56 | −59.6% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 25/12/04 | 25/12/04 | 7,668 sh2 trades | $47.09avg. | $361,078.2 | −2.4% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 25/12/04 | 25/12/04 | 13,278 sh2 trades | $46.84avg. | $621,921.82 | −10.8% | |
VeracyteVCYT | Open-market sale10b5-1 plan | 25/12/04 | 25/12/04 | 1,422 sh2 trades | $47.30avg. | $67,264.02 | −1.8% | |
John LeiteChief Commercial Officer-CLIA | VeracyteVCYT | Open-market sale10b5-1 plan | 25/12/04 | 25/12/04 | 1,278 sh | $47.51 | $60,717.78 | −1.5% |
Evan/ Fa JonesDirector | VeracyteVCYT | Open-market sale10b5-1 plan | 25/11/25 | 25/11/26 | 1,106 sh | $50.25 | $55,576.5 | −3.6% |